Drug Trial Radar · NCT05496738
A Preliminary Study to Evaluate PF-07264660 in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Jun 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
59
Actual
Start
Aug 16, 2022
Primary completion
May 6, 2024
Study completion May 6, 2024
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Aug 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to learn about the safety and effects of study medicine PF-07264660 compared to a placebo. This is the first study of PF-07264660 in humans. All participants in this study will received PF-07264660 or a placebo and it will be assigned by chance. People may be able to participate if they are healthy. The study medicine may be given by shots under the skin or through a vein depending on which group you are assigned to. If you are assigned into Part A, you will receive the study medicine once, stay overnight at the research unit from 3 to 5 overnight stays and you will need to visit the clinic about 11 follow-up visits. Participants will be in this study for up to about 541 days. If you are assigned into Part B, you will receive the study medicine three times, stay overnight at the clinic from 3 to 5 overnight stays and you will need to visit the research unit about 12 follow-up visits. Participants willbe in this study for up to about 561 days.
Conditions
- Healthy
Interventions
PF-07264660 intravenous single ascending doseDrug
PF-07264660 will be administered intravenously in single ascending doses
PF-07264660 subcutaneous multiple ascending doseDrug
PF-07264660 will be administered subcutaneously in multiple ascending doses
Intravenous placeboOther
Placebo will be administered intravenously in single ascending doses
subcutaneous placeboOther
Placebo will be administered subcutaneously in multiple ascending doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment emergent treatment related adverse events (AE's)Time frame: Baseline up to approximately 1.5 years
- Number of participants with treatment emergent treatment-related serious adverse events (SAE's)Time frame: Baseline up to approximately 1.5 years
- Number of participants with change from baseline in blood pressureTime frame: Baseline up to approximately 1.5 years
- Number of participants with change from baseline in pulse rateTime frame: Baseline up to approximately 1.5 years
- Number of participants with change from baseline in temperatureTime frame: Baseline up to approximately 1.5 years
- Number of participants with change from baseline in clinical laboratory valuesTime frame: Baseline up to approximately 1.5 years
- Number of participants with change from baseline in heart rateTime frame: Baseline up to approximately 1.5 years
- Number of participants with change from baseline in QT intervalTime frame: Baseline up to approximately 1.5 years
- Number of participants with change from baseline in corrected QT intervalTime frame: Baseline up to approximately 1.5 years
- Number of participants with change from baseline in PR intervalTime frame: Baseline up to approximately 1.5 years
- Number of participants with change from baseline in QRS intervalTime frame: Baseline up to approximately 1.5 years
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Collaborative Neuroscience Research, LLC
Garden Grove, California
Collaborative Neuroscience Research, LLC
Long Beach, California
Collaborative Neuroscience Research, LLC
Los Alamitos, California
Prism Research LLC dba Nucleus Network
Saint Paul, Minnesota
Clinical Trials of Texas, LLC
San Antonio, Texas
Spaulding Clinical Research
West Bend, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.